MedTrace Logo

Specific PoC Testing of Coagulation in Patients Treated With DOAC 1

NCT02825394 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2020-12-16

No results posted yet for this study

Summary

The investigators study aims to test the correlation between the Cascade Abrazo point-of-care testing (POCT) device (Helena Laboratories, USA) and plasma levels of apixaban, dabigatran, edoxaban and rivaroxaban, and to determine the diagnostic accuracy of POCT to rule out or detect relevant levels of direct oral anticoagulants (DOAC) in real-life patients.

Conditions

  • Anticoagulation With NOAC

Interventions

OTHER

anti-Xa activity point-of-care testing (aXa-POCT)

OTHER

ecarin clotting time point-of-care testing (ECT-POCT)

Sponsors & Collaborators

  • Heart and Diabetes Center North Rhine-Westphalia

    collaborator OTHER

  • University Hospital Tuebingen

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-13
Primary Completion
2021-03-31
Completion
2021-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02825394 on ClinicalTrials.gov